Skip to main content
SpringerLink
Log in

Hepatitis D

  • Chapter
  • First Online:
Book cover Viral Hepatitis in Children

  • 374 Accesses

Abstract

Hepatitis D virus (HDV), or delta virus, is a single-stranded circular RNA virus that is dependent on hepatitis B virus (HBV) surface antigen (HBsAg) for transmission. It is highly pathogenic with a high incidence of progression to cirrhosis and other long-term complications including death. It affects 15–20 million people worldwide despite universal HBV vaccination and due to lack of testing and underrecognition. The standard therapy for treatment is suboptimal in adults, and there are no currently approved treatment modalities for children. Novel research-based therapies including prenylation inhibitors, viral entry inhibitors, and nucleic acid inhibitors have potential to reduce disease morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rizzetto M, Canese M, Arico S (1977) Immunofluorescence detection of a new antigen antibody system (anti-) associated to hepatitis B virus in liver and serum of HBsAg carriers. Gut 18:997–1003

    Article  CAS  Google Scholar 

  2. Rizzetto M, Ponzetto A, Forzani I (1990) Hepatitis delta virus as a global health problem. Vaccine 8(Suppl):S10–S14

    Article  Google Scholar 

  3. Shen L, Gu Y, Sun L et al (2012) Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China. J Med Virol 84(3):445–449. https://doi.org/10.1002/jmv.23212

    Article  CAS  PubMed  Google Scholar 

  4. Liao B, Zhang F, Lin S et al (2014) Epidemiological, clini- cal and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One 9(12):e115888. https://doi.org/10.1371/journal.pone.0115888

    Article  CAS  PubMed  Google Scholar 

  5. Wedemeyer H, Manns MP (2010) Epidemiology, patho- genesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7(1):31–40. https://doi.org/10.1038/nrgastro.2009.205

    Article  PubMed  Google Scholar 

  6. Romeo R, Perbellini R (2015) Hepatitis delta virus: making the point from virus isolation up to 2014. World J Hepatol 7(22):2389–2395. https://doi.org/10.4254/wjh.v7.i22.2389

    Article  PubMed  Google Scholar 

  7. Achievements in Public Health: Hepatitis B Vaccination—United States, 1982–2002 (2002) Centers for Disease Control. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5125a3.htmMMWF. Accessed 12 Jan 2017

  8. Noureddin M, Gish R (2014) Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep 16(1):365. https://doi.org/10.1007/s11894-013-0365-x

    Article  Google Scholar 

  9. Zuckerman AJ (1996) Chapter 70: Hepatitis Viruses. In: Baron S (ed) Medical microbiology, 4th edn. University of Texas Medical Branch at Galveston, Galveston

    Google Scholar 

  10. Su CW, Huang YH, Huo TI et al (2006) Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 130(6):1625–1635

    Article  CAS  Google Scholar 

  11. Alves C, Branco C, Cunha C (2013) Hepatitis delta virus: a peculiar virus. Adv Virol. https://doi.org/10.1155/2013/560105

    Article  Google Scholar 

  12. Hong SY, Chen PJ (2010) Phosphorylation of serine 177 of the small hepatitis delta antigen regulates viral antigenomic RNA replication by interacting with the processive RNA polymerase II. J Virol 84(3):1430–1438. https://doi.org/10.1128/JVI.02083-09

    Article  CAS  PubMed  Google Scholar 

  13. Abbas Z, Afzal R (2013) Life cycle and pathogenesis of hepatitis D virus: a review. World J Hepatol 5(12):666–675. https://doi.org/10.4254/wjh.v5.i12.666

    Article  PubMed  Google Scholar 

  14. Xue MM, Glenn JS, Leung DH (2015) Hepatitis D in children. J Pediatr Gastroenterol Nutr 61(3):271–281. https://doi.org/10.1097/MPG.0000000000000859

    Article  CAS  PubMed  Google Scholar 

  15. Mumtaz K, Ahmed US, Memon S et al (2011) Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J 8:312. https://doi.org/10.1186/1743-422X-8-312

    Article  PubMed  Google Scholar 

  16. Flodgren E, Bengtsson S, Knutsson M et al (2000) Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol 38(9):3311–3316

    CAS  PubMed  Google Scholar 

  17. Mele A, Mariano A, Tosti ME et al (2007) Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti- hepatitis B vaccination campaign. Clin Infect Dis 44(3):e17–e24

    Article  Google Scholar 

  18. Motamedifar M, Taheri M, Lankarani KB et al (2015) The prevalence and risk factors of hepatitis delta virus in HIV/HBV co-infected patients in shiraz, Iran, 2012. Iran J Med Sci 40(5):448–453

    Google Scholar 

  19. Cole SM, Gowans EJ, Macnaughton TB et al (1991) Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen. Hepatology 13(5):845–851

    Article  CAS  Google Scholar 

  20. Lefkowitch JH, Goldstein H, Yatto R et al (1987) Cytopathic liver injury in acute delta virus hepatitis. Gastroenterology 92(5–1):1262–1266

    Article  CAS  Google Scholar 

  21. Guidotti LG, Chisari FV (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1:23–61

    Article  CAS  Google Scholar 

  22. Hughes S, Wedemeyer H, Harrison PM (2011) Hepatitis delta virus. Lancet 378(9785):73–85. https://doi.org/10.1016/S0140-6736(10)61931-9

    Article  PubMed  Google Scholar 

  23. Aslan N, Yurdaydin C, Wiegand J et al (2006) Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 13(8):505–514

    Article  CAS  Google Scholar 

  24. Farci P, Niro GA (2012) Clinical features of hepatitis D. Semin Liver Dis 32(3):228–236. https://doi.org/10.1055/s-0032-1323628

    Article  Google Scholar 

  25. Romeo R, Del NE, Rumi M et al (2009) A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 136(5):1629–1638. https://doi.org/10.1053/j.gastro.2009.01.052

    Article  Google Scholar 

  26. Zachou K, Yurdaydin C, Drebber U (2010) HIDT-1 Study Group, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 30(3):430–437. https://doi.org/10.1111/j.1478-3231.2009.02140.x

    Article  CAS  PubMed  Google Scholar 

  27. Gheorghe L, Iacob S, Simionov I et al (2005) Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol 14(4):329–335

    Google Scholar 

  28. Fattovich G, Giustina G, Christensen E et al (2000) Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 46(3):420–426

    Article  CAS  Google Scholar 

  29. Rosina F et al (1999) Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 117(1):161–166

    Article  CAS  Google Scholar 

  30. Abbas Z, Qureshi M, Hamid S et al (2012) Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol 18(1):18–22. https://doi.org/10.4103/1319-3767.91731

    Article  PubMed  Google Scholar 

  31. Abbas Z, Soomro GB, Hassan SM, Luck NH (2014) Clinical presentation of hepatitis D in Pakistani children. Eur J Gastroenterol Hepatol 26(10):1098–1103. https://doi.org/10.1097/MEG.0000000000000168

    Article  PubMed  Google Scholar 

  32. Ranger-Rogez S, Alain S, Denis F (2002) Hepatitis viruses: mother to child transmission. Pathol Biol (Paris) 50(9):568–575

    Article  CAS  Google Scholar 

  33. Kodani M, Martin A, Mixson-Hayden T et al (2013) One- step real-time PCR assay for detection and quan- titation of hepatitis D virus RNA. J Virol Methods 193(2):531–535. https://doi.org/10.1016/j.jviromet.2013.07.033

    Article  CAS  PubMed  Google Scholar 

  34. Zachou K, Yurdaydin C, Drebber U, HIDT-1 Study Group et al (2010) Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 30(3):430–437. https://doi.org/10.1111/j.1478-3231.2009.02140.x

    Article  CAS  PubMed  Google Scholar 

  35. Pascarella S, Negro F (2011) Hepatitis D virus: an update. Liver Int 31(1):7–21. https://doi.org/10.1111/j.1478-3231.2010.02320.x

    Article  CAS  PubMed  Google Scholar 

  36. Heidrich B, Deterding K, Tillmann HL et al (2009) Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 16(12):883–894. https://doi.org/10.1111/j.1365-2893.2009.01144.x

    Article  CAS  PubMed  Google Scholar 

  37. Arribas JR, Gonzalez-Garcia JJ, Lorenzo A et al (2005) Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 19(13):1361–1365

    Article  CAS  Google Scholar 

  38. Castellares C, Barreiro P, Martín-Carbonero L et al (2008) Liver cirrhosis in HIV-infected patients: prevalence, a etiology and clinical outcome. J Viral Hepat 15(3):165–172. https://doi.org/10.1111/j.1365-2893.2007.00903.x

    Article  CAS  Google Scholar 

  39. Crivelli O, Lavarini C, Chiaberge E et al (1983) Microsomal autoantibodies in chronic infection with the HbsAg-associated delta agent. Clin Exp Immunol 54(1):232–238

    CAS  PubMed  Google Scholar 

  40. Strassburg CP, Obermayer-Straub P, Alex B et al (1996) Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111(6):1576–1586

    Article  CAS  Google Scholar 

  41. Hennes EM, Zeniya M, Czaja AJ, et al; International Autoimmune Hepatitis Group (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48(1):169–176. https://doi.org/10.1002/hep.22322

    Article  Google Scholar 

  42. Rigopoulou E, Zachou K, Gatselis N et al (2013) Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol 13(1):127–135

    Article  Google Scholar 

  43. Fiedler M, Roggendorf M (2001) Vaccination against hepatitis delta virus infection: studies in the wood- chuck (Marmota monax) model. Intervirology 44(2–3):154–161

    Article  CAS  Google Scholar 

  44. Roggendorf M (2012) Perspectives for a vaccine against hepatitis delta virus. Semin Liver Dis 32(3):256–261. https://doi.org/10.1055/s-0032-1323631

    Article  CAS  PubMed  Google Scholar 

  45. Wedemeyer H, Hardtke S, Manns MP (2013) Treatment of hepatitis delta. Clin Liver Dis 2(6):237–239. https://doi.org/10.1002/cld.254

    Article  Google Scholar 

  46. Fawaz R (2010) Hepatitis D and hepatitis E in children. In: Jonas MM (ed) Viral hepatitis in children: unique features and opportunities. In Wu G (ed) Clinical gastroenterology. Springer, Boston, pp 89–110

    Chapter  Google Scholar 

  47. Rosina F, Pintus C, Meschievitz C (1991) A randomized controlled trial of a 12-month course of recombi- nant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 13(6):1052–1056

    Article  CAS  Google Scholar 

  48. Farci P, Roskams T, Chessa L et al (2004) Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126(7):1740–1749

    Article  CAS  Google Scholar 

  49. Farci P, Mandas A, Coiana A et al (1994) Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330(2):88–94

    Article  CAS  Google Scholar 

  50. Heidrich B, Manns MP, Wedemeyer H (2013) Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep 15(1):31–38. https://doi.org/10.1007/s11908-012-0307-z

    Article  PubMed  Google Scholar 

  51. Veronese FM, Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs 22(5):315–329

    Article  CAS  Google Scholar 

  52. Niro GA, Ciancio A, Gaeta GB et al (2006) Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44(3):713–720

    Article  CAS  Google Scholar 

  53. Murray KF, Szenborn L, Wysocki J et al (2012) Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 56(6):2018–2016

    Article  CAS  Google Scholar 

  54. Jonas MM, Chang MH, Sokal E et al (2016) Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology 63(2):377–397. https://doi.org/10.1002/hep.28015, https://doi.org/10.1002/hep.25818

    Article  CAS  Google Scholar 

  55. Wranke A, Wedemeyer H (2016) Antiviral therapy of hepa- titis delta virus infection — progress and challenges towards cure. Curr Opin Virol 20:112–118. https://doi.org/10.1016/j.coviro.2016.10.002

    Article  CAS  PubMed  Google Scholar 

  56. Yurdaydin C, Wedemeyer H, Dalekos G et al (2006) A multicenter randomized study comparing the efficacy of pegylated interferon alfa-2A plus adefovir dipivoxil vs. pegylated interferon alfa-2A plus placebo vs. adefovir dipovoxil for the treatment of chronic delta hepatitis: the intervention trial (HID-IT). Hepatology 41(supplement1):230A

    Google Scholar 

  57. Wranke A, Wedemeyer H (2016) Antiviral therapy of hepatitis delta virus infection — progress and challenges towards cure. Curr Opin Virol 20:112–118. https://doi.org/10.1016/j.coviro.2016.10.002

    Article  CAS  PubMed  Google Scholar 

  58. Lai MM (2005) RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus. J Virol 79(13):7951–7958

    Article  CAS  Google Scholar 

  59. Glenn JS, Watson JA, Havel CM et al (1992) Identification of a prenylation site in delta virus large antigen. Science 256(5061):1331–1333

    Article  CAS  Google Scholar 

  60. Schulze A, Schieck A, Ni Y, Mier W (2010) Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 84(4):1989–2000. https://doi.org/10.1128/JVI.01902-09

    Article  CAS  PubMed  Google Scholar 

  61. Dandri M, Lütgehetmann M (2014) Mouse models of hepatitis B and delta virus infection. J Immunol Methods 410:39–49. https://doi.org/10.1016/j.jim.2014.03.002

    Article  CAS  PubMed  Google Scholar 

  62. Blank A, Markert C, Hohmann N et al (2016) First-in- human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 65(3):483–489. https://doi.org/10.1016/j.jhep.2016.04.013

    Article  CAS  PubMed  Google Scholar 

  63. Urban S, Bartenschlager R, Kubitz R et al (2014) Strategies to inhibit entry o HBV and HDV into hepatocytes. Gastroenterology 147(1):48–64. https://doi.org/10.1053/j.gastro.2014.04.030

    Article  CAS  PubMed  Google Scholar 

  64. Bogomolov P, Alexandrov A, Voronkova N et al (2016) Interim results of a Phase Ib/IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients. J Hepatol 65(3):490–498. https://doi.org/10.1016/j.jhep.2016.04.016

    Article  CAS  PubMed  Google Scholar 

  65. Bordier BB, Ohkanda J, Liu P et al (2003) In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 112(3):407–414

    Article  CAS  Google Scholar 

  66. Koh C, Canini L, Dahari H et al (2015) Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 15(10):1167–1174. https://doi.org/10.1016/S1473-3099(15)00074-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Al-Mahtab M, Bazinet M, Vaillant A (2016) Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One. https://doi.org/10.1371/journal.pone.0156667

    Article  Google Scholar 

  68. Bazinet M, Pâtea V, Cebotarescu V, et al. Significant Reduction of HBsAg and HDV RNA by the Nucleic Acid Polymer REP 2139 in Caucasian Patients with Chronic HBV/HDV Co-infection. Oral presentation presented at the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna Austria, 22–26 April 2015

    Google Scholar 

  69. Mederacke I, Filmann N, Yurdaydin C et al (2012) Rapid early HDV RNA decline in the peripheral blood but pro- longed intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol 56(1):115–522. https://doi.org/10.1016/j.jhep.2011.06.016

    Article  CAS  PubMed  Google Scholar 

  70. Samuel D, Zignego AL, Reynes M et al (1995) Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 21(2):333–339

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Texas Children’s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

    Keisha R. Barton & Daniel H. Leung

Authors
  1. Keisha R. Barton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel H. Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel H. Leung .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, National Taiwan University College of Medicine, Taipei, Taiwan

    Mei-Hwei Chang

  2. Department of Pediatrics, Johns Hopkins University School of Mediine, Baltimore, MD, USA

    Kathleen B. Schwarz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barton, K.R., Leung, D.H. (2019). Hepatitis D. In: Chang, MH., Schwarz, K. (eds) Viral Hepatitis in Children. Springer, Singapore. https://doi.org/10.1007/978-981-13-0050-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-0050-9_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-0049-3

  • Online ISBN: 978-981-13-0050-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation